COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Coya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.20−0.05 (-1.18%)
Close on Oct 19, 2026
- Market cap
- $98.52M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
33.1%
8M of 23M shares
Institutional holders
54
5 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dr. Reddy's Laboratories Limited | 2,272,727 | 9.70% | 13G (passive) | Jan 30, 2026 |
| DME Advisors GP, L.L.C. | 1,651,440 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| David Einhorn | 1,274,026 | 8.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COYA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| DME Capital Management, LP | 2,335,540 | 9.96% | $13.66M | – | 0.35% |
| Vanguard Capital Management LLC | 842,220 | 3.59% | $4.93M | −2,693 | 0.00% |
| Alyeska Investment Group, L.P. | 800,000 | 3.41% | $4.68M | – | 0.01% |
| AIGH Capital Management LLC | 631,912 | 2.69% | $3.70M | −343,492 | 0.23% |
| CM Management, LLC | 400,000 | 1.71% | $2.34M | +25,000 | 1.56% |
| Private Management Group Inc | 384,217 | 1.64% | $2.25M | +15,121 | 0.06% |
| Marshall Wace, Llp | 249,793 | 1.06% | $1.46M | +24,001 | 0.00% |
| Geode Capital Management, LLC | 228,243 | 0.97% | $1.34M | −5,159 | 0.00% |
| Renaissance Technologies LLC | 192,986 | 0.82% | $1.13M | +89,022 | 0.00% |
| Prosight Management, LP | 170,000 | 0.72% | $994.50K | −250,360 | 0.17% |
| Dimensional Fund Advisors LP | 155,917 | 0.66% | $913.04K | +59,998 | 0.00% |
| Vanguard Fiduciary Trust Co | 129,551 | 0.55% | $757.87K | −10,335 | 0.00% |
| Jones Financial Companies Lllp | 110,910 | 0.47% | $610.01K | +65,950 | 0.00% |
| BlackRock, Inc. | 102,408 | 0.44% | $599.09K | +19,639 | 0.00% |
| Prelude Capital Management, LLC | 101,330 | 0.43% | $592.78K | – | 0.04% |
| JBF Capital, Inc. | 100,006 | 0.43% | $585.04K | – | 0.08% |
| Royal Bank of Canada | 93,414 | 0.40% | $546.00K | +80,022 | 0.00% |
| Morgan Stanley | 82,106 | 0.35% | $480.32K | −3,594 | 0.00% |
| State Street Corp | 79,813 | 0.34% | $466.91K | – | 0.00% |
| Susquehanna International Group, Llp | 61,006 | 0.26% | $356.89K | +21,690 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 54 | 8M | 33.1% | 5 / 14 | 16 / 7 | 0M | 1M |
| Q1 2026 | 56 | 8M | 34.6% | 12 / 20 | 11 / 12 | 2M | 1M |
| Q4 2025 | 58 | 8M | 33.8% | 29 / 19 | 5 / 7 | 4M | 0M |
| Q3 2025 | 36 | 5M | 20.3% | 7 / 11 | 7 / 4 | 0M | 0M |
| Q2 2025 | 33 | 4M | 19.2% | 7 / 11 | 7 / 0 | 0M | 0M |
| Q1 2025 | 26 | 5M | 19.9% | 5 / 10 | 4 / 5 | 0M | 0M |
| Q4 2024 | 26 | 4M | 18.9% | 8 / 11 | 5 / 1 | 1M | 0M |
| Q3 2024 | 19 | 3M | 14.1% | 3 / 3 | 6 / 2 | 0M | 0M |
| Q2 2024 | 19 | 3M | 13.9% | 4 / 4 | 7 / 4 | 0M | 0M |
| Q1 2024 | 19 | 3M | 14.2% | 4 / 9 | 3 / 4 | 2M | 0M |
| Q4 2023 | 21 | 3M | 12.0% | 6 / 10 | 2 / 0 | 1M | 0M |
| Q3 2023 | 15 | 1M | 6.0% | 4 / 7 | 3 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of COYA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 601,117 | 2.56% | $3.52M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 219,955 | 0.94% | $1.29M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 108,636 | 0.46% | $523.63K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 75,558 | 0.32% | $316.59K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 65,909 | 0.28% | $385.57K | 0.03% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 37,158 | 0.16% | $155.69K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 33,438 | 0.14% | $161.17K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 24,066 | 0.10% | $116.00K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 14,892 | 0.06% | $71.78K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 13,107 | 0.06% | $54.92K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 10,902 | 0.05% | $63.78K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 10,246 | 0.04% | $59.94K | 0.00% | Jun 30, 2026 |
| Schwab Total Stock Market Index Fund | 10,000 | 0.04% | $41.90K | 0.00% | Jul 31, 2026 |
| Dimensional US Vector Equity ETF | 4,793 | 0.02% | $20.08K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 4,435 | 0.02% | $25.94K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Howard Berman | Executive Chairman, Director | 949,338 | 4.05% | Jan 26, 2026 |
| Arun Swaminathan | Chief Executive Officer, Director | 10,000 | 0.04% | Jan 26, 2026 |
| David S. Snyder | Chief Financial Officer | 8,800 | 0.04% | Jan 26, 2026 |
| Fred Grossman | Chief Medical Officer | 2,710 | 0.01% | Jan 26, 2026 |
| Mark H. Pavao | Director | – | – | Apr 9, 2026 |
| Ann Lee | Director | 33,958 | 0.14% | Jan 6, 2026 |
| Wilbur L. Ross Jr | Director | 165,016 | 0.70% | Jan 6, 2026 |
| Dieter Weinand | Director | – | – | Jan 6, 2026 |
| Dov A. Goldstein Md | Director | 27,557 | 0.12% | Jan 6, 2026 |
| Anabella Villalobos | Director | 10,000 | 0.04% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dov A. Goldstein Md Director | Aug 18, 2025 | Option exercise | +17,557 | $1.09 | $19.14K | 27,557 |
| David S. Snyder Chief Financial Officer | Nov 14, 2024 | Buy | +1,800 | $7.19 | $12.94K | 8,800 |
| Arun Swaminathan Chief Executive Officer, Director | Nov 13, 2024 | Buy | +5,000 | $7.36 | $36.80K | 10,000 |
| Arun Swaminathan Chief Executive Officer, Director | Nov 11, 2024 | Buy | +5,000 | $7.34 | $36.70K | 5,000 |
| Fred Grossman Chief Medical Officer | Nov 11, 2024 | Buy | +2,710 | $7.37 | $19.97K | 2,710 |
| Ann Lee Director | Aug 22, 2023 | Buy | +1,000 | $3.62 | $3.62K | 17,479 |
| Ann Lee Director | Jan 3, 2023 | Conversion | +6,479 | $4.00 | $25.92K | 16,479 |
| Ann Lee Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Howard Berman Chief Executive Officer, Director, 10% owner | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Dov A. Goldstein Md Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| David S. Snyder Chief Financial Officer | Jan 3, 2023 | Buy | +7,000 | – | – | 7,000 |
| Anabella Villalobos Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Hideki Garren Director | Jan 3, 2023 | Buy | +2,000 | – | – | 2,000 |
| Adrian Hepner Chief Medical Officer | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.